Browsing by Subject "Metilfenidat"
Now showing items 1-2 of 2
-
CES1 and SLC6A2 genetic variants as predictors of response to methylphenidate in autism spectrum disorders
(Pharmacogenomics and personalized medicine, 2022, vol. 15, p. 951-957, 2022-11)Purpose Autistic spectrum disorders (ASD) children and adolescents usually present comorbidities, with 40–70% of them affected by attention deficit hyperactivity disorders (ADHD). The first option of ... -
Pharmacogenetic influences on the response to pharmacological treatment in autism spectrum disorders
(Journal of Translational Genetics and Genomics, 2021, 5:278-287, 2021-07)Aim: About a third of patients with autism spectrum disorder (ASD) receive pharmacological treatment for comorbid symptoms. However, 30%-50% do not respond adequately and/or present severe and long-lasting ...